Plasma exchange is generally not used in the treatment of chronic glomerulonephritis; it is mostly used in the treatment of acute glomerulonephritis of type I and III, pulmonary hemorrhagic nephritis syndrome, lupus nephritis, purpuric nephritis, IgA nephropathy, membranoproliferative nephritis and acute rejection of transplanted kidneys, and other conditions. Chronic glomerulonephritis, referred to as chronic nephritis, is characterized by proteinuria, hematuria, hypertension, and edema, with different onset modalities and slow progression of the disease, with varying degrees of renal impairment, and some patients will eventually develop to end-stage renal failure. In general, plasma exchange is not used to treat chronic glomerulonephritis. Currently, plasma exchange is mostly used for the treatment of type I and type III acute progressive glomerulonephritis, pulmonary hemorrhagic nephritis syndrome, lupus nephritis, purpuric nephritis, IgA nephropathy, membranoproliferative nephritis, and acute rejection of transplanted kidneys. When the above diseases cannot be completely controlled by hormones and other immunosuppressive drugs, plasma exchange can remove anti-glomerular basement membrane antibodies, anti-nuclear antibodies and various anti-autoantibodies, immune complexes and inflammatory products accompanying immune reactions, so that the clinical symptoms, renal function and histological changes can be improved to a certain extent. However, it is not recommended to be used in cases where renal failure has already occurred. It is recommended that patients with chronic glomerulonephritis seek medical attention in a timely manner and follow the doctor’s instructions for standardized diagnosis and treatment to avoid delays.